TRCT
EIGR

Tower Research Capital (TRC)’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Tower Research Capital (TRC)’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,948
Closed -$9.75K – 6171
2024
Q1 		$9.75K Buy
1,948
+1,339
+220% +$8.31K ﹤0.01% 3798
2023
Q4 		$4.11K Buy
609
+59
+11% +$519 ﹤0.01% 4991
2023
Q3 		$5.03K Buy
550
+22
+4% +$442 ﹤0.01% 4774
2023
Q2 		$11.2K Sell
528
-22
-4% -$678 ﹤0.01% 4008
2023
Q1 		$15K Buy
550
+291
+112% +$13.5K ﹤0.01% 3844
2022
Q4 		$9K Buy
259
+150
+138% +$18K ﹤0.01% 4315
2022
Q3 		$25K Sell
109
-40
-27% -$9.83K ﹤0.01% 3777
2022
Q2 		$28K Sell
149
-81
-35% -$16.3K ﹤0.01% 3462
2022
Q1 		$58K Sell
230
-703
-75% -$111K ﹤0.01% 2616
2021
Q4 		$145K Buy
933
+45
+5% +$8.7K ﹤0.01% 1990
2021
Q3 		$178K Buy
888
+815
+1,116% +$194K ﹤0.01% 1923
2021
Q2 		$19K Buy
73
+21
+40% +$5.24K ﹤0.01% 3960
2021
Q1 		$14K Sell
52
-16
-24% -$5.04K ﹤0.01% 4174
2020
Q4 		$25K Sell
68
-609
-90% -$175K ﹤0.01% 3738
2020
Q3 		$165K Buy
677
+546
+417% +$170K ﹤0.01% 2750
2020
Q2 		$37K Buy
131
+129
+6,450% +$38K ﹤0.01% 3289
2020
Q1 		$0 Buy
+2
New +$638 ﹤0.01% 4114
2019
Q4 		– Sell
-18
Closed -$5K – 4566
2019
Q3 		$5K Sell
18
-145
-89% -$47.1K ﹤0.01% 3355
2019
Q2 		$52K Buy
163
+154
+1,711% +$53.3K ﹤0.01% 1555
2019
Q1 		$4K Sell
9
-101
-92% -$40.5K ﹤0.01% 3222
2018
Q4 		$33K Buy
110
+55
+100% +$17.8K ﹤0.01% 1586
2018
Q3 		$20K Buy
55
+47
+588% +$16.1K ﹤0.01% 2360
2018
Q2 		$3K Buy
+8
New +$2.85K ﹤0.01% 3267
2018
Q1 		– Sell
-186
Closed -$77K – 3978
2017
Q4 		$77K Buy
+186
New +$66.5K 0.01% 1039
2017
Q3 		– Sell
-5
Closed -$1K – 4231
2017
Q2 		$1K Sell
5
-36
-88% -$8.18K ﹤0.01% 2531
2017
Q1 		$14K Buy
+41
New +$14.1K ﹤0.01% 1568
2016
Q4 		– Sell
-5
Closed -$2K – 4521
2016
Q3 		$2K Buy
+5
New +$2.55K ﹤0.01% 3164
2016
Q2 		– Sell
-3
Closed -$1K – 5110
2016
Q1 		$1K Sell
3
-28
-90% -$13.9K ﹤0.01% 3832
2015
Q4 		$20K Hold
31
– – ﹤0.01% 1307
2015
Q3 		$14K Buy
31
+6
+24% +$3.18K ﹤0.01% 2052
2015
Q2 		$14K Buy
25
+18
+257% +$49.8K ﹤0.01% 2421
2015
Q1 		$57K Buy
+7
New +$61.2K 0.01% 1370
2014
Q4 		– Hold
0
– – – 4832
2014
Q3 		– Sell
-1
Closed -$5.28K – 4186
2014
Q2 		$8K Sell
1
-5
-83% -$25K ﹤0.01% 2552
2014
Q1 		$33K Buy
+6
New +$28.4K ﹤0.01% 1420

Other funds holding EIGR

PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Tower Research Capital (TRC)'s EIGR Position: Q2 2024 in Review

Tower Research Capital (TRC) sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2024, closing a stake of 1,948 shares — an estimated $9.75K sold.

Tower Research Capital (TRC) first reported a position in EIGR in Q1 2014 and held it in 34 quarters. The position peaked at $178K in Q3 2021. 2 funds tracked by Wall St. Rank hold EIGR as of Q2 2024.

  • Tower Research Capital (TRC) reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 1,948 Eiger BioPharmaceuticals, Inc. shares in Q2 2024, an estimated $9.75K.
  • Tower Research Capital (TRC) first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2014 and held it in 34 quarters.
  • Tower Research Capital (TRC)'s Eiger BioPharmaceuticals, Inc. position peaked at $178K in Q3 2021.
  • 2 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2024.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2024, filed 13 Aug 2024.